Regeneron Pharmaceuticals Inc.’s Covid-19 antibody drug was authorized Saturday by U.S. health regulators, the second cleared this month to treat patients who aren’t hospitalized but are at high risk of developing severe disease.
The Food and Drug Administration cleared the antibody drug cocktail for use treating mild to moderate Covid-19 patients 12 years of age and older, including people older than 65 years.
Regeneron’s…
This post first appeared on wsj.com
